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Background: Little is known about psychological impact of disclosing lifestyle-related diseases. Previous studies
discussed the long-term psychological impact of disease disclosure, and a significant psychological impact was not
observed.
This study clarified the psychological impact on anxiety state of patients when lifestyle-related diseases are disclosed
at general checkups for local residents.
In particular, this study evaluated the short-term impact on patients, and how the notification of abnormal values
and the disclosure of disease at general checkups affect patients’ subsequent behavioral changes.
Methods: The study design was a prospective cohort study. We compared the anxiety state of participants using a
self-administered anxiety assessment scale, State–Trait Anxiety Inventory (STAI), before and after Physician’s explanation
of abnormal values in markers of lifestyle-related diseases. The participants were those between the age of 40 and
75 years who underwent general checkups at two primary care facilities. In addition, we assessed the effects on
lifestyle habits and the psychological impact caused by general checkup using STAI and a survey on behavioral
changes one month after the checkup.
Results: The valid response rate at the survey of the general checkup was 92% (534/578). Of those who showed
abnormal levels in markers of lifestyle-related diseases, anxiety was augmented significantly among those who
responded that the physician had told them of their diagnosis compared to those who responded that the physician
had not told them of their diagnosis (Wilcoxon rank-sum test, P < 0.007). The percentage of patients whose state
anxiety scale of STAI increased ≥5 points was 30% in the disease disclosed group (33/111) and 17% in the disease
undisclosed group (27/159), respectively. The risk ratio was 1.5 (95% CI: 1.1–2.0). One month after the general
checkup, overall anxiety diminished regardless of whether diagnosis of lifestyle-related diseases was disclosed to
patients notified of abnormal values. In addition, improvements in daily life behaviors as a result of notification of
abnormalities or disclosure of diagnosis at general checkup were not observed.
Conclusion: Even in a general checkup for the general population, disclosing non-critical diseases such as
lifestyle-related diseases exacerbated anxiety as a short-term psychological impact.
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In 2008, the new system of mandatory health checkups
in Japan called “specific health checkups” was launched
to screen for lifestyle-related disease [1,2], the cost of
which is covered by local governments. In general, the
primary purpose of “health checkups” is to discover
disease in early stages, which can lead to improved treat-
ment efficacy. However, according to a meta-analysis
conducted by Krogsbøll et al. in 2012 [3], general
checkups do not decrease mortality and morbidity, sug-
gesting that their effects still need validation.
From the perspective of psychological impact on indi-
viduals, the aforementioned meta-analysis found that
only two studies reported relevant results using scales
that measure psychological distress, with no significant
impact observed [4,5]. However, these previous studies
discussed the long-term (1–5 years) psychological effect,
and thus the short-term psychological impact remains
unknown. Krogsbøll et al. also indicated that over-diagnosis
may further augment patients’ anxiety [3]. In addition,
previous long-term studies investigated patients who
were already receiving care from a medical institution.
In other words, these studies were clinic- or hospital-
based. In contrast, the new system of general health
checkups for local Japanese residents includes those
without regular care from medical institutions. Thus, it
includes many residents who feel healthy or who do not
actively seek medical care on their own. Furthermore,
while many studies have assessed the impact of disclos-
ing diseases that affect short-term life prognosis, such
as cancer [6-8], most diseases found during general
checkups are lifestyle-related diseases, such as dysli-
pidemia or diabetes, that affect long-term prognosis.
Among lifestyle-related disease, only the long-term
effects of labeling individuals as having hypertension
have been evaluated. In that report, individuals labeled
as having hypertension complain of symptoms of
depression significantly more often than those who are
not [9]; however, the psychological impact of disclosing
other lifestyle-related diseases is not clear.
The main objective was to measure anxiety levels
(state and trait) before and after consultation when
lifestyle-related diseases are disclosed at general checkups
for local residents. In addition, we evaluated how the
notification of abnormal values and the disclosure of
disease at general checkups affect patients’ subsequent
behavioral changes.
Methods
Study design, setting and participants
This was a prospective cohort study that assessed psy-
chological status over time, before and after a general
checkup, using a self-administered survey. The study was
conducted at two facilities—a family physician teachingclinic responsible for primary care and a family physician
teaching hospital with a 150-bed inpatient facility—in
Kita-ku, Tokyo, a district with a large population of elderly
residents approximately 15 km north of central Tokyo.
Health checkups were conducted intensively between June
and October 2011, and self-administered questionnaire as-
sessments were conducted at three time points: before
and after the explanation of the checkup results, and one
month after the checkup. Instead of an intervention study,
the observational study design was chosen because it
may be ethically difficult to allocate “no notification”
and/or “no disclosure” to participants, and this study
focused on the psychological impact from the partici-
pants’ perspective.
The system of general health checkups for screening
lifestyle-related diseases in Japan, called “specific health
checkup”, is as follows: All adults aged 40 years or older
who are covered by public health insurance are sent a
voucher from the government office of their resident
district to receive the health checkups for lifestyle-
related diseases, and individuals are to undergo the
checkup at a specified medical institution within their
district. When individuals visit a medical institution for
consultation in this district, they are eligible to receive
blood pressure measurement, blood tests, chest X-ray,
electrocardiogram, and urine test, free of charge. For the
blood test results, values that deviate from pre-determined
standard values are automatically identified by a computer,
and are output and printed on the results sheet. The gen-
eral checkup results are explained and guidance is given
to the participants by the physician based on the results
sheet at the institution where the participants received the
general checkup.
Study participants comprised adults aged 40 years or
older, but less than 75 years, who received this health
checkup between June and October 2011 at one of the
two specified facilities, and who did not regularly visit a
medical institution and agreed to participate in the
study. Those who had difficulty filling out the question-
naire due to reduced visual acuity and those who had
been diagnosed with dementia were excluded. The target
lifestyle-related diseases in this study were diabetes, dys-
lipidemia, hypertension, and hyperuricemia.
This study was approved by the Ethics Committee of
Ouji Coop Hospital (approval number 41). A bulletin
was posted in front of the medical room to provide in-
formation about the study, and informed consent was
obtained verbally from all participants. The participant
selection process is illustrated in Figure 1.
Measurement variables and evaluation process
The anxiety state of the patient was evaluated using a
self-administered questionnaire, the State–Trait Anxiety
Inventory (STAI), before the physicians explained the
Number of people who 
received general checkup: 
1302
Those who do not regularly 
visit the medical institution: 
579
Not notified of abnormal 
values: 233
Those who regularly visit the 
medical institution for some 
type of disease or condition: 
553
Disease disclosed: 111Those notified of abnormal
values but disease 
undisclosed: 159
Those notified of abnormal 
values in markers of 
lifestyle-related diseases: 270
Blank data
Did not agree to participate in
the study: 43
Those who agreed to 
participate in the study, were 
notified of lifestyle-related 
disease, and were able to 
return the survey 1 month 
later: 217
Valid responses: 90
Those notified of abnormal 
values but disease 
undisclosed: 55
Disease disclosed: 35
Those with abnormal values in 
markers of lifestyle-related 
diseases but not aware of 
them: 55
Those notified of abnormal 
values in markers of diseases 
other than lifestyle-related 
diseases: 33
Notified of abnormal values: 303
Figure 1 The participant selection process and number of participants.
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is described in the Instruments section. The participant’s
lifestyle habits were assessed using a self-administered
questionnaire by determining the stages of behavioral
change described by Prochaska [10]. Patients were classified
into one of five stages: pre-contemplation, contemplation,preparation, action, or maintenance [11,12]. The stages of
behavioral change are assessed for diet, exercise, drinking,
smoking, and seeking medical care and are compared
before and one month after of the general checkup. We
developed a questionnaire that asks participants about
their behavioral stages for each of diet, exercise, drinking,
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scored on a scale from 4 to 0 and compared before and
one month after the general checkup. If participants’
answer was “Precontemplation stage”, it was scored as
4. The rest of the stages were scored as follows: “Con-
templation stage” as 3, “Preparation stage” as 2, “Action
stage” as 1, and “Maintenance stage” as 0.
The questions were as follows:
Diet: What do you think about improving your diet
behavior?
Exercise: What do you think about exercising for
30 min at least twice a week?
Seeking medical care: What do you think about seeing
a doctor regularly?
Drinking: Appropriate drinking is up to 20 g of alcohol
(180 ml of Japanese sake) each day, and the general
recommendation is to abstain from drinking alcohol
twice a week. What do you think about this habit?
Smoking: What do you think about quitting smoking?
For questions about drinking and smoking, since the
question is concerned about addictive behavior, we
excluded the stage of maintenance according to its
definition that the stage extends from six months to an
indeterminate period.
Participant’s characteristics (gender, age), screening for
depression (two questions) were also assessed using an
additional questionnaire.
Immediately after a physician explained the partici-
pant’s results from the health checkups, his/her anxiety
state was evaluated again using STAI. An additional
questionnaire was also administered to ask whether the
physician had told the participants of any abnormal re-
sults or had diagnosed a lifestyle-related disease, and if
so, what the diagnosis was.
The purpose of this study was masked from the physi-
cians who explained the results of general checkups to
participants, and they were given instructions to approach
the participants as they normally would. The automatic
assessment criteria for abnormal levels were determined
according to the International Diabetes Federation (IDF)
standard from 2005 and Third Report of the National
Cholesterol Education Program Adult Treatment Panel III
(NCEP-ATPIII) standards [14], and were as follows:
≥130/85 mmHg for hypertension, ≥150 mg/dL for tri-
glycerides, <40 mg/dL (men) and <50 mg/dL (women)
for HDL-c, and ≥100 mg/dL for plasma glucose. The
abnormal level for uric acid for both men and women
was >7.0 mg/dL, which is the upper normal limit com-
monly used in Japan [15]. HbA1c was also considered as
a marker for diabetes, and HbA1c ≥6.5% (NGSP) was
determined as abnormal [16,17]. In addition, consi-
dering the possibility that the level of abnormality inmarkers is likely to have an effect on the physician’s
explanation to a participant, we also conducted analysis
for only those with mild abnormality (mild group) since
the farther the result is from the reference value, the
more confidently and assertively a physician would ex-
plain the result and diagnosis. Those with mild abnor-
mality were not in the stage that would generally
require immediate treatment at medical consultations
in Japan, but had borderline high values that require
attention according to NCEP-ATP III and AHA guide-
lines [11,18,19]. The following values were used as
criteria to determine mild abnormalities: systolic blood
pressure of 140–159 mm Hg and diastolic blood pres-
sure of 90–99 mm Hg for hypertension, triglycerides of
150–199 mg/dL and LDL of 150–159 mg/dL for dyslip-
idemia, and HbA1c (NGSP) of 6.5–7.0% for diabetes
[16,17]. In those who were pointed out to have a high
marker for uric acid, patient recollections were usually
concerned with hyperuricemia treatment that would
usually apply to patients with a history of gout; there-
fore, uric acid levels were not used as a criterion of mild
abnormality.
The collection staff monitored participants as they
filled out the self-administered questionnaire before and
after the general checkup, and the questionnaires were
recovered from all participants in front of the medical
room after the checkup. One month after the general
checkup results were explained to a study participant at
a physician’s consultation, a questionnaire was mailed to
those who had abnormal levels in markers of lifestyle-
related disease. The replies are sorted into those who
were notified of abnormalities in markers or who were
notified of a diagnosis of lifestyle-related disease. This
questionnaire included STAI, as well as additional ques-
tions on stages of behavioral changes in diet, exercise,
drinking, smoking, and seeking medical care, and whether
or not their lifestyle habits had improved. Explanation to
the participants was given as “the questionnaire is asking
whether your lifestyle has changed after the health
checkup and about anxiety change before and after the
health checkup. The questionnaire strictly focuses on the
health checkup, and answers would not affect any action
resulting from your regular consultation.”
The questionnaire was filled out by the study partici-
pants and returned by mail. Self-administered question-
naires that contained blanks or were difficult to evaluate
were treated as missing data and were excluded from
the analysis.
In the present study, patients were directly asked
whether they were notified of abnormalities by the phys-
ician, and whether the diagnosis was disclosed to them.
The reason why the physicians were not surveyed about
their decision for participants’ results was that conduct-
ing a survey for the physicians who explained the results
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disclosure would affect their clinical practice style during
the study period, potentially creating a bias. As this study
focuses on a natural process of doctor–patient interaction,
the purpose of this study was obliged to be concealed to
doctors. In addition, the purpose of the present study was
not to investigate the intervention effect by disclosing the
diagnosis to patients but to focus on the psychological
impact of general checkup results on patients based on
the patient’s perception. In addition, it may be ethically
difficult to allocate “no notification” and/or “no disclosure”
as physicians’ behavior to participants. Therefore, we
considered that the impact of disease disclosure should be
evaluated from the perspective of the patients first.
Instruments
STAI, developed in 1966 using Spielberger’s theory, is a
40-item questionnaire that measures both state anxiety
and trait anxiety. State anxiety is an anxiety state
induced in a short period of time by situations that are
perceived as harmful. Trait anxiety is an anxiety state
caused by one’s innate personality. In the present study,
both state anxiety and trait anxiety were assessed by
state-Trait Anxiety Inventory (Japanes version) [20,21]
to determine whether the anxiety state was greatly
affected by the patient’s innate personality or induced by
purely being notified of a disease condition.
Size of study
In order to test the hypothesis that anxiety was induced by
receiving notifications of an abnormality or disease at a
general checkup, the number of samples required to con-
duct the study was determined in advance. Each question
in STAI is rated on one of the following 4-point scales
(listed in increasing point value): “very much so, moderately
so, somewhat, not at all” or “almost never, sometimes,
often, almost always”. Scores of 1–4 points are added, and
the total scores range from 20 to 80. The total score is clas-
sified into the following five levels of anxiety: very high,
high, normal, low, and very low. There are approximately
10 points between each of these levels. When the mean
change in the STAI score upon receiving notification at the
general checkup was assumed to be 5 points and standard
deviation (SD) was assumed to be 15, the number of sam-
ples statistically required for the study became 190 for one
group (α = 0.05, β = 0.10). In order to compare the groups
of people whose anxiety was induced versus not induced,
the number of samples required became 380. Therefore,
the target sample number was set to approximately 400.
Analysis and statistical methods
The following two aspects were assessed for: 1) whether
the participant’s anxiety scale STAI score is affected; and
2) whether there are behavioral changes in daily lifestyle.1) Participants were divided into three groups: those
not notified of any abnormalities in markers of
lifestyle-related disease through automatic assessment
(hereinafter “no abnormality group”), those notified of
abnormalities and were told of the disease diagnosis
by the physician (“disease disclosed group”), and those
notified of abnormalities but were not told of the
disease by the physician (“notified of abnormality/
disease undisclosed group”). Whether or not the
changes in state of anxiety are different between
each of the two groups was determined using Student’s
t test for parametric data and the Wilcoxon rank-sum
test for nonparametric data. Bonferroni correction for
multiple comparisons was applied in this case. The
Shapiro–Wilk test was used to determine whether the
data were parametric or nonparametric. As shown in
Figure 1, those who responded that they were notified
of abnormalities in diseases other than lifestyle-related
diseases were excluded from the analysis. For changes
in state of anxiety, in order to evaluate the independent
impact of disease diagnosis disclosure, logistic
regression analysis adjusting for gender, age, depressed
mood, loss of interest, trait anxiety, diabetes,
hyperlipidemia, hypertension, and hyperuricemia as
covariates was conducted [22]. Logistic regression
analysis was similarly conducted in a group of
participants limited to those with mild abnormalities
in lifestyle-related disease markers. The anxiety
assessment scale STAI was used in the present
study, and its results were classified into five levels
with each level approximately ten points apart. A
higher total score indicates higher anxiety, with the
five levels having anxiety levels of very high, high,
normal, low, and very low. In the logistic regression
analysis, we constructed two models, one using the
five levels that are approximately ten points apart in
each level and another using half-levels that are
approximately five points apart in each level as
outcome development of clinically significant
changes in state anxiety.
2) Changes in lifestyle habits one month after the
explanation of general checkup results between
the notified of abnormality/disease undisclosed
group and disease disclosed group were compared
using the Wilcoxon rank-sum test. In addition,
Spearman’s correlation coefficients were used to
elucidate the association between change of state
anxiety before and just after the checkup, and
changes of behavioral stages one month after the
checkup.
All statistical analyses were performed using STATA/
SE version 10.1. P < 0.05 was considered to be statisti-
cally significant [23].
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There were 449 participants from the first site (clinic)
and 853 from the second site (hospital), and 242 out of
the 449, and 337 out of the 853 participants did not
regularly visit a medical institution and agreed to partici-
pate in this study. The characteristics of participants in
this prospective cohort study are shown in Table 1. The
male-to-female ratio was 182:321. The mean age (±SD)
was 62 ± 9 years. Many participants were around retire-
ment age, which is around 60–65 years in Japan.
Approximately 60% of the participants had abnormal
values in markers of lifestyle-related disease, and dis-
eases were disclosed to less than half of these partici-
pants. As shown in Figure 2, state anxiety before and
after explanation of the results by the physician was
compared in no abnormality, notified of abnormality
/disease undisclosed, and disease disclosed groups. In no
abnormality and notified of abnormality/disease undis-
closed groups, the state anxiety decreased after partici-
pants received an explanation of the results. In contrast,
state anxiety was exacerbated in the disease disclosed
group.
Statistically, state anxiety was also augmented signifi-
cantly in the disease disclosed group compared to the no-
tified of abnormality/disease undisclosed group (Wilcoxon
rank-sum test, P < 0.007). Moreover, in both comparisons
between the no abnormality group and notified of abnor-
mality/disease undisclosed group, and between the no ab-
normality group and disease disclosed group, the disease
undisclosed and disease disclosed groups showed a signifi-
cantly augmented state anxiety compared to the no abnor-
mality group (Wilcoxon rank-sum test, P < 0.001).
The percentage of patients whose state anxiety scale of
STAI (maximum score: 80) increased ≥5 points was 30%
in the disease disclosed group (33/111) and 17% in the
disease undisclosed group (27/159), respectively. TheTable 1 Characteristics of patients
Total No. abnorm
group
Number of patients 503 233
Gender (male/female) 182/321 68/165
Age (Mean age ± SD) 62.2 ± 9.1 61.9 ± 9
Number of patients by disease*
Hypertension 57 (11%) 17 (7%)
Dyslipidemia 169 (34%) 43 (18%
Diabetes 23 (4%) 1 (0.4%
Hyperuricemia 35 (7%) 7 (3%)
With or without depression tendency
Depression tendency 106 (21%) 38 (16%
*One patient may be afflicted by more than one disease. For “with or without depressi
regarding depression (loss of interest, depressed mood) were considered to have a dep
SD: standard deviation.risk ratio was 1.5 (95% CI: 1.1–2.0). After adjusting for
gender, age, depressed mood, loss of interest, trait anx-
iety, diabetes, hyperlipidemia, hypertension, and hyper-
uricemia as covariates in a logistic regression model
(Table 2), the odds ratio of state anxiety increasing by
≥5 points due to disease disclosure was 2.1 (95% CI:
1.1–4.0). Similarly, the odds ratio of state anxiety in-
creasing by ≥10 points was 3.0 (95% CI: 1.2–7.0). This
indicated that disease disclosure augments state anxiety
even after taking into consideration trait anxiety, which
indicates anxiety tendency due to innate personality. In
addition, logistic analysis adjusted for covariates was
similarly conducted in the mild group, and showed that
the risk of state anxiety increasing by ≥5 points was sig-
nificantly elevated in the disease disclosed group (odds
ratio 3.1, 95% CI: 1.2–8).
The mailed survey recovery rate one month after
the general checkup was 42% (90/217). State anxiety
significantly decreased in both those who are notified of
abnormal levels of lifestyle-related disease markers or
whose disease was disclosed at one month after the gen-
eral checkup compared to right after the checkup
(paired t test, P < 0.015, P < 0.006, respectively). State
anxiety at one month after the checkup was not signifi-
cantly different between the notified of abnormality/dis-
ease undisclosed group and disease disclosed group
(Student’s t test, P < 0.85).
Between those who responded to the mailed question-
naire at one month after and those who did not, neither
the change of state anxiety nor trait anxiety before and
just after the general checkup showed any significant dif-
ference (Wilcoxon rank sum, P < 0.11).
The percentage of participants who responded that
there was an improvement in their own lifestyle habits
one month after the general checkup was 40.0% for the






.4 62.0 ± 9.0 63.3 ± 8.9
24 (15%) 16 (14%)
) 71 (45%) 55 (50%)
) 9 (6%) 13 (12%)
15 (9%) 13 (12%)
) 35 (22%) 33 (30%)
on tendency”, patients who answered yes to either or both of the two questions
ression tendency.
Figure 2 Comparison of changes in state anxiety before and after general checkup (no abnormality, notified of abnormality/disease undisclosed,
and disease disclosed groups). The x-axis of the histograms in the left and middle columns represents the state anxiety score on the STAI. The
histograms in the right column indicate changes between before and after general checkup results were explained by the physician. The graphs
in the right column are skewed to the left with increased anxiety and skewed to the right with decreased anxiety.
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that significant differences were not observed between
the two groups (Wilcoxon rank-sum test). Figure 3
shows the comparison between before and one month
after the general checkup on whether lifestyle habits
such as diet, drinking, exercise, smoking, and seeking
medical care actually improved. Significant improve-
ments were not observed in any of these variables. There
was no statistically significant difference in Spearman’s
correlation coefficients between the change of state
anxiety and changes of behavioral stages.
Discussion
The patient’s anxiety state is augmented more by dis-
closure of disease “labeling”, or diagnosis from the phys-
ician at a general checkup than by a simple notification
of abnormal values. Excluding the effects of potential
confounding variables such as anxiety traits or depres-
sive states associated with personality and types of
lifestyle-related diseases also led to similar results. Add-
itionally, even with mild deviations in the abnormal test
values, disease diagnosis disclosure elicited an anxiety
state in patients. Despite these results, improvements in
daily life behavior due to the perception of abnormalitynotification or diagnosis disclosure were not observed
one month after the general checkup. The results of the
present study showed that, even in a general checkup
for the general population, disclosing non-critical dis-
eases such as lifestyle-related diseases exacerbated anx-
iety as a short-term psychological impact.
Anxiety state is thought to be affected by many factors.
In particular, anxiety state related to personality, namely
trait anxiety, is an important variable that should be
adjusted as a confounding factor. Therefore, in order to
elucidate the independent impact of disease diagnosis
disclosure on anxiety state, adjustments for trait anxiety,
gender, age, depressed mood, loss of interest, kinds of
diseases were conducted as covariates. The results indi-
cated that diagnosis disclosure augmented the patients’
anxiety state independent of the effects from these
possible covariates. However, other factors that affect
the patient–physician relationship, such as duration of
consultation, the specific method in which the physician
discloses information, and the amount and content of
the explanation aside from disease disclosure, were not
assessed in the present study, and these may have
affected the results. In particular, from the perspective of
































































Notified Abnormality/Disease Undisclosed Group
Notified Abnormality/Disease Undisclosed Group Disease Disclosed Group Notified Abnormality/Disease Undisclosed Group
Changes in Exercise habit
Figure 3 Improvements in lifestyle habits one month after general checku
each of the lifestyle habits. If the stages of behavioral changes were not di
general checkup, the value was 0. If the behavioral changes improved by o
Table 2 Analysis of factors that affect changes in anxiety
STAI state anxiety
increased by 5 points
STAI state anxiety
increased by 10 points
Unadjusted
Risk Ratio (95% CI) Risk Ratio (95% CI)
With disease
disclosure
1.4 (1.10–1.97) 1.60 (1.16–2.22)
Adjusted
Odds Ratio (95% CI) Odds Ratio (95% CI)
With disease
disclosure
2.09 (1.10–3.99) 2.97 (1.25–7.02)
Gender 1.49 (0.74–3.01) 1.58 (0.62–4.04)
Age 0.98 (0.94–1.01) 0.97 (0.93–1.02)
Depressed mood 0.47 (0.14–1.48) 0.67 (0.14–3.27)
Loss of interest 0.88 (0.22–3.57) 1.51 (0.23–9.88)
Hypertension 1.28 (0.54–3.02) 1.47 (0.48–4.49)
Dyslipidemia 1.05 (0.55–2.01) 1.35 (0.57–3.20)
Diabetes 1.52 (0.43–5.37) 1.99 (0.45–8.80)
Hyperuricemia 0.66 (0.20–2.17) 0.87 (0.21–3.51)
Trait anxiety 0.97 (0.93–1.01) 0.93 (0.88–0.98)
STAI: State-Trait Anxiety Inventory.
CI: Confidence interval.
Table 2 Shows the comparison of logistic analysis results adjusted for
covariates between the abnormality notified/disease undisclosed and disease
disclosed groups in order to elucidate whether disclosing disease increases
state anxiety.
Tominaga et al. BMC Family Practice  (2015) 16:60 Page 8 of 10the points that must be considered is that a physician
may be more apt to disclose the disease to patients when
there is a greater deviation from normal test values.
However, even when we analyzed participants whose test
results were in the “mild” range, anxiety was augmented
due to disease disclosure. Therefore, disclosing the
diagnosis was found to exacerbate anxiety, even if there
was only mild abnormality in lifestyle-related disease
markers.
This study has considered the differences in the com-
prehension of one’s own health state between local resi-
dents and patients registered at a clinic. This has
revealed how local resident’s notification of abnormal
values for lifestyle-related disease markers and diagnosis
disclosure truly affect those who consider themselves
healthy or believe they are not ill. Although we investi-
gated the disclosure of lifestyle-related diseases that are
not directly life threatening in the early stages, there was
a negative psychological impact on local residents who
must be more sensitive to labeling than patients regu-
larly visiting a clinic, similar to the psychological impact
of patient labeling by cancer diagnosis [6-8]. This may
be attributed in part to physicians who are not aware of
the psychological impact of the diagnosis of lifestyle-
related diseases on patients, especially on local residents.
In the future, the explanation of lifestyle-related disease
results while considering the psychological impact on
patients, similar to disclosing a cancer diagnosis, will be
necessary.-4 -2 0 2 4
ing medical care
















Changes in drinking activityGraphs by diagnosis
Disease Disclosed Group
Disease Disclosed Group Notified Abnormality/Disease Undisclosed Group Disease Disclosed Group
p. The y-axis of the graphs represents stages of behavioral changes in
fferent one month after the general checkup compared to before the
ne stage, then the value was 1.
Tominaga et al. BMC Family Practice  (2015) 16:60 Page 9 of 10It was also suggested that lifestyle habits might not be
improved one month after the general checkup despite a
low follow-up rate. From the results of behavioral
changes one month after the checkup, improvements in
daily life behaviors were not observed despite patients’
perception that they were notified of abnormal values or
disclosed a diagnosis at general checkup. There was no
indication in the present study that patients with higher
anxiety score made greater attempts to improve their be-
havior. Moreover, at one month after, overall anxiety had
decreased in patients who were notified of abnormalities
regardless of the disclosure of lifestyle-related disease by
the physician, demonstrating that anxiety merely increased
temporarily immediately after the general checkup. This
result most likely indicates that, depending on the method,
notification of abnormal values and diagnosis disclosure at
general checkups do not necessarily elicit improvements
in behavior, but rather temporarily augments psycho-
logical anxiety. One reason for this is that physicians may
be uniformly disclosing the diagnosis regardless of the
severity. In other words, this may be augmenting anxiety
in those with mild illnesses while greater intervention may
not be performed in those with severe illnesses. If anxiety
alone is augmented without improvements in lifestyle
habits due to general checkup results, then this deviates
from the idea of conducting general checkups with the
primary purpose to discover lifestyle-related diseases early
and prevent them. Considering the results of this study,
further studies to evaluate the way of delivering the infor-
mation to motivate people should be done soon. It is also
an immensely important issue that only a few participants
sought to improve their health one month after the health
checkup. This issue has to be further examined as well.
There are several limitations to this study. The ques-
tionnaire response rate by mail at one month after
general checkup was low. Thus, it may be difficult to draw
definitive conclusions on behavioral changes after the
general checkup. Among non-responders to the mailed
questionnaire, however, the change of anxiety between
before and just after the general checkup was not
significantly different from that among responders,
which means responders had no specific characteristics
on anxiety change against labeling. Moreover, even if
non-responders might be less motivated to modify their
lifestyle than those who responded, labeling could have
made less of an impact than observed. In addition, the
details of the study population, specifically whether it
deviated from the entire resident population, could not
be analyzed. Although the specific health checkup is
mandatory, the percentage of those who receive it is not
necessarily 100%; thus, the study population may comprise
many people who are particularly interested in their own
health. Moreover, because the study investigated those
who are able to receive checkups on weekdays, employeeswho have difficulty receiving checkups on weekdays are
thought to be absent from the study population. This
was considered the reason why more women received
checkups. However, at the very least, there were no sig-
nificant differences in the changes in anxiety between
men and women. Another limitation is that the lifestyle
behavior was evaluated by a self-rating questionnaire of
behavioral stages, and not by the actual behaviors or
specific indices such as calorie consumption or physical
activity.
Future investigations should be conducted on the
method in which general checkup results are explained,
keeping in mind that the manner in which lifestyle-
related diseases are disclosed or in which patients are
notified of abnormal values may augment patients’ psy-
chological anxiety.
Conclusion
Even in a general checkup for the general population,
disclosing non-critical diseases such as lifestyle-related
diseases exacerbated anxiety as a short-term psychological
impact. In the future, the explanation of lifestyle-related
disease results while considering the psychological impact
on patients will be necessary.
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